NCT07420426 · RECRUITING
Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment
This trial is testing whether an automated therapy program delivered by instant message on a smartphone can help people with mild cognitive impairment manage neuropsychiatric symptoms like anxiety, depression, and irritability. It uses Acceptance and Commitment Therapy principles, adapted for delivery by text or voice message. This is a Phase N/A trial, meaning it is focused on testing feasibility and early effectiveness rather than being a late-stage confirmatory study.
You may qualify if
- Community-dwelling adults aged ≥ 50 years
- HK-MoCA score ranged from 18 to 22
- MBI-C ≥7
- SCD-9 ≥3
- IADL =18
- Able to read and communicate in Chinese
- Able to use the text or voice messaging function on a smartphone
You're excluded if
- Clinical diagnosis of dementia
- Clinical diagnosis of psychiatric disease
- Currently participating in any type of psychological or behavioural intervention for NPSs
- Currently taking psychiatric medication
- Currently receiving acute care or post-acute hospitalization care
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-18